$PTHS News

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc (NYSEARCA:PTHS) Revenue Beats Estimates in Q1 2026, Net Loss Narrows

Pelthos Therapeutics Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate

Pelthos Therapeutics Appoints John M. Gay As CFO

Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain

Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...

Pelthos Therapeutics Q4 Earnings Call Highlights

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

Pelthos Therapeutics Inc. (PTHS) Reports Strong Q4 2025 Earnings Beat Amid Muted Market Reaction

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Piper Sandler Initiates Coverage On Pelthos Therapeutics with Overweight Rating, Announces Price Target of $48